164 related articles for article (PubMed ID: 15774813)
1. Survival after brain metastases from breast cancer in the trastuzumab era.
Kirsch DG; Ledezma CJ; Mathews CS; Bhan AK; Ancukiewicz M; Hochberg FH; Loeffler JS
J Clin Oncol; 2005 Mar; 23(9):2114-6; author reply 2116-7. PubMed ID: 15774813
[No Abstract] [Full Text] [Related]
2. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
[No Abstract] [Full Text] [Related]
3. [Brain metastases in breast cancer: a special disease course for HER2 positive tumors].
Hurkens KP; Hupperets PS; Creemers GJ; Erdkamp FL; van de Vijver KK; Tjan-Heijnen VC
Ned Tijdschr Geneeskd; 2008 Dec; 152(50):2701-6. PubMed ID: 19192581
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab in CNS progressive metastatic breast cancer.
Tosoni A; Franceschi E; Esposti RD; Brandes AA
Future Oncol; 2007 Aug; 3(4):367-9. PubMed ID: 17661709
[No Abstract] [Full Text] [Related]
5. Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer.
Altundag K; Altundag O; Atik MA; Morandi P; Gunduz M
Breast; 2005 Oct; 14(5):425. PubMed ID: 16216749
[No Abstract] [Full Text] [Related]
6. Comment on: incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
Errante D; Bernardi D; Bianco A; Salvagno L
Acta Oncol; 2007; 46(4):565-6. PubMed ID: 17497328
[No Abstract] [Full Text] [Related]
7. Brain metastases in patients receiving trastuzumab for breast cancer.
Salmaggi A; Silvani A; Boiardi A
Neurol Sci; 2007 Mar; 28(1):1. PubMed ID: 17385088
[No Abstract] [Full Text] [Related]
8. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
Yau T; Swanton C; Chua S; Sue A; Walsh G; Rostom A; Johnston SR; O'Brien ME; Smith IE
Acta Oncol; 2006; 45(2):196-201. PubMed ID: 16546866
[TBL] [Abstract][Full Text] [Related]
9. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
Stemmler HJ; Schmitt M; Willems A; Bernhard H; Harbeck N; Heinemann V
Anticancer Drugs; 2007 Jan; 18(1):23-8. PubMed ID: 17159499
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
[TBL] [Abstract][Full Text] [Related]
11. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab.
Colozza M; Minenza E; Gori S; Fenocchio D; Paolucci C; Aristei C; Floridi P
Cancer Chemother Pharmacol; 2009 May; 63(6):1157-9. PubMed ID: 18987856
[No Abstract] [Full Text] [Related]
12. Brain metastases in patients receiving trastuzumab for breast cancer.
Errante D; Bernardi D; Bianco A; Salvagno L
Neurol Sci; 2007 Mar; 28(1):52-3. PubMed ID: 17385098
[No Abstract] [Full Text] [Related]
13. Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
Church DN; Modgil R; Guglani S; Bahl A; Hopkins K; Braybrooke JP; Blair P; Price CG
Am J Clin Oncol; 2008 Jun; 31(3):250-4. PubMed ID: 18525303
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome?
Tosoni A; Franceschi E; Brandes AA
Crit Rev Oncol Hematol; 2008 Dec; 68(3):212-21. PubMed ID: 18550383
[TBL] [Abstract][Full Text] [Related]
15. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
Niwińska A; Tacikowska M; Murawska M
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1134-9. PubMed ID: 19932944
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer.
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Breast; 2006 Apr; 15(2):219-25. PubMed ID: 16026983
[TBL] [Abstract][Full Text] [Related]
17. Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: "It hurts to be on the cutting edge".
Belkacémi Y; Gligorov J
Radiother Oncol; 2010 Jan; 94(1):119-20; author reply 120-1. PubMed ID: 19410315
[No Abstract] [Full Text] [Related]
18. HER2 in brain metastases: issues of concordance, survival, and treatment.
Fuchs IB; Loebbecke M; Buhler H; Stoltenburg-Didinger G; Heine B; Lichtenegger W; Schaller G
J Clin Oncol; 2002 Oct; 20(19):4130-3. PubMed ID: 12351617
[No Abstract] [Full Text] [Related]
19. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Unal OU; Mert AG; Bilici M; Ozkan M; Elkiran ET; Yaman S; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Urakci Z; Buyukberber S
Oncology; 2012; 83(3):141-50. PubMed ID: 22814315
[TBL] [Abstract][Full Text] [Related]
20. Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab.
Munzone E; Nolè F; Sanna G; Goldhirsch A
Breast; 2005 Oct; 14(5):380-3. PubMed ID: 16216740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
